<p>Dynamics of Epicardiac Fat and Heart Function in Type 2 Diabetic Patients Initiated with SGLT-2 Inhibitors</p>

• DOI: 10.2147/dmso.s223629
• Publication Date: 2019-12-04T23:15:41Z
• Authors: Adina Braha; Bogdan Timar; Laura Diaconu; Raluca Lupusoru; Lucian Vasiluta; Alexandra Sima; Adrian Vlad; Mircea Munteanu; Alin Albai; Daniela Cipu; Romulus Timar
• Keywords: 03 medical and health sciences; epicardiac fat; 0302 clinical medicine; RC581-951; heart failure; Specialties of internal medicine; diastolic dysfunction; Targets and Therapy [Diabetes, Metabolic Syndrome and Obesity]; Original Research; 3. Good health

The aim of this study was to assess the dynamics epicardiac adipose tissue (EAT) thickness and total volume as well that systolic diastolic dysfunction in a group patients with type 2 diabetes (T2D) after initiation sodium glucose co-transporter (SGLT 2) inhibitors therapy.This prospective, observational included 53 T2D who received SGLT-2 for 24 weeks. In all patients, echocardiographic screening EAT, non-contrast computed tomography scans were performed, both before weeks inhibition. Imagistic evaluation followed by association's analysis between EAT heart function, patient's clinical biological parameters. We considered decrease or increase more than 10% being clinically significant.The mean decreased significantly SGLT inhibition (37.8±17.2 vs. 20.7±7 cm3; p<0.001). Median values also (5.95 3.01 mm; Most 75.4% (40/53), presented volume, 9.5% (5/53) had stable values, while 15.1% (8/53) means increased. 73.5% 1 (DD 1) at baseline. No significant change observed left ventricular ejection fraction treatment. Although not statistically significant, an improvement cardiac function has been noticed throughout duration year treatment inhibitors.This showed beneficial effect on short period treatment, but there no changes during 1st study. However, reducing epicardial fat led remission dysfunction.